🏢 官网IRIOVAQwen · 实盘不做把握 9/10不做原因:不是事件
北京时间·🕒 发布 09-04(美东日)仅日期·⟳ 抓取 09-05 20:24:25回填·⚡ 决策 09-13 01:27:49·44.8 天前
Iovance（IOVA.US）发布IR日程稿：高管将于9月10日Wells Fargo医疗大会及9月15日H.C. Wainwright全球投资大会演讲，无新增经营或财务事实
读完正文全文即可判定：这是典型的会议日程型 IR 新闻稿，公司只是预告高管将在两场投资者会议上演讲并给出直播链接，正文中除既有公司背景介绍（Amtagvi 获批状态、治疗中心数量等早已公开的信息）外没有任何新增经营、临床、监管或财务事实，因此不存在事件研究方向，也不存在可量化的 materiality。Web、内部 KB 与行情都不可能把一条无信息量的日程公告变成有正期望的交易；同时信号已滞后 8 天，第一场会议已结束，时效窗口亦不成立。故直接输出完整 AVOID，不再调用查重、行情或先例工具。
📄 原文IOVA↗ 原文
Iovance Biotherapeutics to Present at Upcoming Conferences
September 4, 2026 at 8:00 AM EDT PDF Version SAN CARLOS, Calif. , Sept. 04, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherape…
不做 Iovance Biotherapeutics（IOVA.US）
会议日程型 IR 公告，正文无任何新增经营/临床/监管/财务事实，不构成事件催化，方向与 edge 均不存在；且信号已滞后8天、9月10日那场会议已结束、美股当刻周末闭市，时效与执行窗口同样不成立。若后续 9/15 演讲或公司另发实质性披露（Amtagvi 商业化数据、管线注册进展、融资安排），应作为独立信号重新研判。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
事实：2026-09-04 08:00 EDT，Iovance（IOVA.US）IR 页与 GlobeNewswire 同步发布新闻稿，宣布高管出席 Wells Fargo 第21届医疗大会（9/10 炉边对话）与 H.C. Wainwright 第28届全球投资大会（9/15 演讲），并提供网络直播/存档链接；正文其余部分为公司背景与前瞻性声明模板。影响链：会议出席日程本身不改变公司收入、指引、临床读出、监管状态、产能或资本结构，市场对该类公告的历史反应近似零，属于纯程序性 IR 通讯；即便会议上出现实质表态，那也是发生在 9/10 之后的独立事件，需以彼时的具体内容重新研判，不能由本条日程稿承载。价格/证据：无需行情——没有增量事实可供定价，也没有可界定的入场触发点。结论：无事件、无方向、无可交易 edge，AVOID。
🔎 新鲜度:最早出现 2026-09-04 · 扩散 low · price-in 风险 low ↗
关键理由
- 本条信号只是高管参会日程预告，不含任何指引、订单、临床或监管新增事实，无法形成方向判断。
- 既有公司背景描述（Amtagvi 获批、95+ 治疗中心）均为早已公开信息，不构成 surprise 或重定价催化。
- 信号时间 9/4、当前 9/12，第一场会议已于 9/10 结束，事件研究与交易窗口均已失效。
主要风险
- 若 9/10 Wells Fargo 炉边对话或 9/15 H.C. Wainwright 演讲中披露了商业化放量、管线注册或融资相关的新口径，应作为独立信号重新研判；该风险与本条日程公告无关，不能作为本次交易理由。
先例如何影响了这次决策
对本次决策的影响:先例缺失未改变结论——结论由事件本身无增量事实直接决定，属 NO_EVENT 早停，不依赖统计基率。
方向:无可用先例；投资者会议出席日程公告属公认的非事件类别，不构成需要定价的催化。
涨幅量级:无：不存在可测量的事件反应幅度，也未调用 event_study（无真实同类首发事件可锚）。
形态:不适用；本条无入场结构，不存在见光死/高开低走的判断需求。
原文全文
展开原文 · 4,142 字
September 4, 2026 at 8:00 AM EDT
PDF Version
SAN CARLOS, Calif.
,
Sept. 04, 2026
(GLOBE NEWSWIRE) --
Iovance Biotherapeutics, Inc.
(NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences:
Wells Fargo 21st Annual Healthcare Conference
Fireside Chat:
September 10, 2026
, at
11:00 a.m. ET
Boston, MA
H.C. Wainwright
28th Annual
Global Investment Conference
Presentation:
September 15, 2026
, at
4:00 p.m. ET
New York, NY
The live and archived webcast will be available at
https://ir.iovance.com/news-events/events-presentations
.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics
, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi
®
(lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 95 authorized treatment centers. The
Iovance TIL platform
spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. For more information, please visit
www.iovance.com
.
Amtagvi® and its accompanying design marks, Proleukin
®
, Iovance
®
, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.
Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on
www.iovance.com
.
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “achievable,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
CONTACTS
Investors
IR@iovance.com
650-260-7120 ext. 150
Media
PR@iovance.com
650-260-7120 ext. 150
PDF Version
SAN CARLOS, Calif.
,
Sept. 04, 2026
(GLOBE NEWSWIRE) --
Iovance Biotherapeutics, Inc.
(NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences:
Wells Fargo 21st Annual Healthcare Conference
Fireside Chat:
September 10, 2026
, at
11:00 a.m. ET
Boston, MA
H.C. Wainwright
28th Annual
Global Investment Conference
Presentation:
September 15, 2026
, at
4:00 p.m. ET
New York, NY
The live and archived webcast will be available at
https://ir.iovance.com/news-events/events-presentations
.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics
, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi
®
(lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 95 authorized treatment centers. The
Iovance TIL platform
spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. For more information, please visit
www.iovance.com
.
Amtagvi® and its accompanying design marks, Proleukin
®
, Iovance
®
, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.
Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on
www.iovance.com
.
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “achievable,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
CONTACTS
Investors
IR@iovance.com
650-260-7120 ext. 150
Media
PR@iovance.com
650-260-7120 ext. 150
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。